Medpace (NASDAQ:MEDP) CEO Sells $1,229,916.09 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 1,983 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $620.23, for a total transaction of $1,229,916.09. Following the sale, the chief executive officer directly owned 545,217 shares in the company, valued at approximately $338,159,939.91. This represents a 0.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Medpace Stock Performance

MEDP traded down $6.66 during midday trading on Tuesday, hitting $613.37. The company had a trading volume of 246,088 shares, compared to its average volume of 346,263. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The company has a market capitalization of $17.12 billion, a PE ratio of 35.95, a P/E/G ratio of 2.77 and a beta of 1.15. The firm’s 50-day simple moving average is $553.21 and its 200-day simple moving average is $492.40.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Medpace

Several institutional investors and hedge funds have recently made changes to their positions in MEDP. Johnson Financial Group Inc. bought a new stake in shares of Medpace in the 2nd quarter valued at $27,000. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Elyxium Wealth LLC bought a new position in Medpace during the fourth quarter worth about $30,000. Jones Financial Companies Lllp acquired a new position in Medpace in the second quarter valued at about $30,000. Finally, Allied Private Wealth LLC acquired a new position in Medpace in the second quarter valued at about $31,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on MEDP shares. Robert W. Baird upped their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a report on Thursday, July 23rd. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and raised their target price for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Truist Financial lifted their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Finally, Mizuho boosted their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.